All News
Night Splinting for Carpal Tunnel (3.24.2023)
Mar 24, 2023
Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com. This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.
Read Article
Spondyloarthritis Innovations
Mar 21, 2023
The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.
Read Article
⚠️Beware not all bone marrow oedema =#AxSpA on MRI !
Signal seen in 17% volunteers at SIJs
@DrPoddubnyy
#RNL2023 https://t.co/rksQin3tmD
Mar 19, 2023
Future treatment for #AxSpA ?
Promising data for #Bimekizumab
Inhibits IL-17 A and F
#RNL2023 https://t.co/H2euMPgIFj
Mar 19, 2023
Dr. John Reveille on genetic sharing between AS, PsO, and IBD
- multiple overlapping genetic signals
@RheumNow #RNL2023 https://t.co/p3gvfTO732
Mar 19, 2023
Late onset Inflammatory back pain?, Reveille #RNL2023 @RheumNow https://t.co/G0LOgjmBvj
Mar 19, 2023
Great tips for #AxSpA monitoring
and
🚩 red flags for radiographic progression 🚩
❌No need for routine imaging follow-up
#RNL2023 @deodhara https://t.co/PAFtHIrqRF
Mar 19, 2023
Is AS transmission to offspring more common from the mother or father?
- hard to say, some studies (including Swiss and UK studies) show mothers play a larger role
- other studies show fathers do
@RheumNow #RNL2023 https://t.co/Vr1qUy5Y6b
Mar 19, 2023
AxSpA is primarily a genetic disease
- clusters in families, especially HLA-B27+ first degree relatives
- genetic testing for asymptomatic relatives not recommended
@RheumNow #RNL2023 https://t.co/vhBlNlXMHR
Mar 19, 2023
Awareness increased for this disease , BY Atul Deodhar #RNL2023 @RheumNow https://t.co/MSBrYU5Pb4
Mar 19, 2023
#RNL2023 @RheumNow
Atul Deodhar:
Prevalence of AS is increasing!
Is it truly more? Or likely better recognized and diagnosed, as well as increased recognition of nr-AxSpa https://t.co/qNwUg5RtaG
Mar 19, 2023
Atul Deodhar's "3-4-5" Rule for MRI Sacroiliac Jts (SIJ)
Erosion in 3+ SIJ quadrants
Bone marrow edema 4+ SIJ quadrants
Fat lesion in 5+ SI joint
@Rheumnow #RNL2023 https://t.co/AHZUhhEmmC
Mar 19, 2023
Dr. Deodhar reminds us of his "3,4,5 rule" for diagnosing AS.
*Erosions in 3 or more SIJ quadrants
*BME in 4 or more SIJ quadrants
*Fat lesions in 5 of more SIJ quadrants
#RNL2023 @RheumNow https://t.co/2m8TmkQo0A
Mar 19, 2023
Dr. Atul Deodhar on AxSpA
- 5-40% of nr-axSpA progress to r-axSpA over 2-10 years
- is non-radiographic axSpA a misnomer?
@RheumNow #RNL2023 https://t.co/bhwlbg6eWN
Mar 19, 2023
Risk factors for radiographic progression:
Men ♂️
Smoking 🚬
Active inflammation🔥
Blue collar workers 💪
HLA-B27+ 💉
Pre-existing syndesmophyte 🩻
Atul Deodhar at #RNL2023 @RheumNow https://t.co/9ibHTEhi9k
Mar 19, 2023
No significance difference in radiographic progression in patients with IL17-TNF , BY Atul Deodhar #RNL2023 @RheumNow https://t.co/S3NQ4mWgjt
Mar 19, 2023
SURPASS: SEC vs ADA for axSpA
Outcome: %pts with no radiographic progression
Not benefit- Secukinumab not better than adalimumab
Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well!
@RheumNow #RNL2023 https://t.co/Vt58jSXCMd
Mar 19, 2023
First Head-to-Head bDMARD study in axSpA to assess radiographic progression
- secukinumab vs. adalimumab biosimilar
- 66% of either arm prevented radiographic progression
- no difference between two arms but good news is radiographic progression is low!
@RheumNow #RNL2023 https://t.co/xq8GhN7kzr
Mar 19, 2023
Late breaking ACR abstract '22 SURPASS study (H2H TNFi vs IL17 in AS radiographic progression.) Primary endpoint was not met.
However, Dr. Deodhar's take away: spinal radiographic progression over 2 years is very low despite high disease activity in both txs! #RNL2023 @RheumNow https://t.co/TsukRs29pC
Mar 19, 2023
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS
- it works but is it different from existing IL-17i?
- appears to work well in TNFi-inadequate responders
- are TNFi-IR pts immunologically different? niche category for IL-17A and F use?
@RheumNow #RNL2023 https://t.co/dWkakahHAi
Mar 19, 2023